Actelion Ltd. (ATLN), the Swiss drugmaker that gets almost 90 percent of sales from a treatment for a rare lung disease, said Andre Muller will replace Chief Financial Officer Andrew Oakley, who is leaving the company. Muller, 49, will start the position on Sept. 1, the Allschwil-based company said in a statement today. Oakley, 51, is leaving to “focus on opportunities outside Actelion,” the drugmaker said.
Help employers find you! Check out all the jobs and post your resume.
